ПРОФИЛАКТИКА ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ ПОСЛЕ КАТЕТЕРНОЙ АБЛАЦИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ С ПОМОЩЬЮ ДАБИГАТРАНА
Аннотация
В обзорной статье освещены результаты наиболее крупных исследований, касающиеся сравнения эффективности и безопасности применения дабигатрана и варфарина для профилактики тромбоэмболических осложнений у пациентов, подвергшихся радиочастотной катетерной аблации фибрилляции предсердий.
Об авторах
С. Е. МамчурРоссия
доктор медицинских наук
заведующий лабораторией нарушений ритма сердца и электрокардиостимуляции
Адрес для переписки:
Мамчур С. Е., 650002, г. Кемерово, Сосновый бульвар, д. 6. Тел. 8(3842) 64-35-38
Е. В. Горбунова
Россия
Д. А. Щербинина
Россия
М. П. Романова
Россия
Список литературы
1. Диагностика и лечение фибрилляции предсердий: рекомендации РКО, ВНОА и АССХ / Рос. кардиол. об-во, Всерос. науч. об-во специалистов по клин. электрофизиологии, аритмологии и кардиостимуляции, Ассоц. сердечно-сосудистых хирургов. М., 2012. 100 с.
2. Клинические рекомендации по проведению электрофизиологических исследований, катетерной аблации и применению имплантируемых антиаритмических устройств. Изд. 4-е. М.: ГЭОТАР-Медиа, 2013. 596 с.
3. A Head-to-Head Comparison of Periprocedural Coagulability Under Anticoagulation with Rivaroxaban Versus Dabigatran in Patients Undergoing Ablation of Atrial Fibrillation / A. Sairaku [et al.] // Clin. Drug. Investig. 2013. Vol. 33. P. 847–853.
4. Assessing arrhythmia burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS study / S. Kapa [et al.] // J. Cardiovasc. Electrophysiol. 2013. Vol. 24 (8). P. 875–881.
5. Catheter Ablation of Atrial Fibrillation Without Dabigratan Discontinuation: Preliminary Safety and Efficacy Data / L. Di Biaise [et al.] // Circulation. 2011. Vol. 124. P. A14277.
6. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation / S. Schneeweiss [et al.] // Cardiovasc Qual Outcomes. 2012. Vol. 5(4). P. 480–486.
7. Dabigatran in patients post atrial fibrillation ablation / C. Eitel [et al.] // JACC. 2012. Vol. 59. Abstr. 1235–1296.
8. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness / A. R. Kansal [et al.] // Thromb Haemost. 2012. Vol. 108(4). P. 672–682.
9. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion / R. Nagarakanti [et al.] // Circulation. 2011. Vol. 123. P. 131–136.
10. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation / J. S. Kim [et al.] // Heart Rhythm. 2013. Vol. 10. P. 483–489.
11. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study / A. Verma [et al.] // JAMA Intern. Med. 2013. Vol. 173(2). P. 149–156.
12. Feasibility & Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation: Results from a Multicenter Prospective Registry / D. Lakkireddy [et al.] // J. Am. Coll. Cardiol. 2013. pii: S0735-1097(13)06543-1. [Epub ahead of print].
13. Hohnloser S. H., Camm A. J. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature // Europace. 2013. Vol. 15 (10). P. 1407–1411.
14. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design / H. Calkins [et al.] // Europace. 2012. Vol. 14. P. 528–606.
15. Impact of atrial fibrillation on the risk of death: the Framingham Heart study / E. J. Benjamin [et al.] // Circulation. 1998. Vol. 98. P. 946–952.
16. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study / C. Herrera Siklódy // J. Am. Coll. Cardiol. 2011. Vol. 58(7). P. 681–688.
17. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation / G. Y. H. Lip // J. Am. Coll. Cardiol. 2012. Vol. 60. P. 738–746.
18. Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial / J. P. Piccini [et al.] // J. Am. Coll. Cardiol. 2013. Vol. 61. P. 1998–2006.
19. Pradaxa Can Be Safely Used As Monotherapy Or As A Bridge To Therapeutic Warfarin After Atrial Fibrillation Ablation / T. J. Bunch [et al.] // Circulation. 2011. Vol. 124. P. A14708.
20. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications / W. M. Feinberg [et al.] // Arch. Intern. Med. 1995. Vol. 155. P. 469–473.
21. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation / J. Cosedis Nielsen [et al.] // N. Engl. J. Med. 2012. Vol. 367 (17). P. 1587–1595.
22. Radiofrequency ablation vs antiarrhythmic drugs as firstline treatment of symptomatic atrial fibrillation: A randomized trial / O. M. Wazni [et al.] // JAMA. 2005. Vol. 293. Р. 2634–2640.
23. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins / M. Haissaguerre [et al.] // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.
24. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study / T. J. Wang [et al.] // Circulation. 2003. Vol. 107. P. 2920–2925.
25. The use of dabigatran immediately after atrial fibrillation ablation / R. A. Winkle [et al.] // J. Cardiovasc. Electrophysiol. 2012. Vol. 23. P. 264–268.
26. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses / H. Calkins [et al.] // Circ. Arrhythm. Electrophysiol. 2009. Vol. 2. P. 349–361.
27. Use of Dabigatran for Peri-Procedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial fibrillation: A New Paradigm in Peri-Procedural Anticoagulation / M. Bassiouny [et al.] // Circulation. 2011. Vol. 124. P. A13128.
28. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation / H. Yamaji [et al.] // Clin. Drug. Investig. 2013. Vol. 33. P. 409–418.
Для цитирования:
Мамчур С.Е., Горбунова Е.В., Щербинина Д.А., Романова М.П. ПРОФИЛАКТИКА ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ ПОСЛЕ КАТЕТЕРНОЙ АБЛАЦИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ С ПОМОЩЬЮ ДАБИГАТРАНА. Комплексные проблемы сердечно-сосудистых заболеваний. 2014;(1):59-66. https://doi.org/10.17802/2306-1278-2014-1-59-66
For citation:
Mamchur S.E., Gorbunova E.V., Scherbinina D.A., Romanova M.P. PREVENTION OF THROMBOEMBOLIC COMPLICATIONS AFTER ATRIAL FIBRILLATION CAT HETER ABLATION USING DABIGATRAN. Complex Issues of Cardiovascular Diseases. 2014;(1):59-66. (In Russ.) https://doi.org/10.17802/2306-1278-2014-1-59-66